DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS 📋 Regulatory Action / Label Change
The September 2026 Fast Track designations span several oncology settings, including KRAS-mutated solid tumors, non-small cell lung cancer (NSCLC), relapsed/refractory high-risk myelodysplastic syndromes (MDS), sarcoma, and prostate cancer diagnostics. Fast Track status is intended to facilitate development and regulatory review of products addressing serious conditions with unmet medical needs.
Key Regulatory Developments
- KST-6051, an oral pan-KRAS inhibitor, received Fast Track designation for advanced or metastatic KRAS-mutated solid tumors and is currently being evaluated in the Phase 1 FALCON trial.
- Cesalatamig, a PD-1/VEGF bispecific antibody, received Fast Track designation for NSCLC progressing after PD-(L)1-directed immunotherapy and platinum-based chemotherapy.
- LYT-200, an anti-galectin-9 monoclonal antibody combined with a hypomethylating agent, received designation for relapsed/refractory high-risk MDS following encouraging early clinical development.
- SOT106, an antibody-drug conjugate, received Fast Track designation for sarcoma based on preclinical development data.
- Plinabulin plus docetaxel received Fast Track designation for previously treated advanced or metastatic nonsquamous NSCLC following immunotherapy and platinum-based chemotherapy.
- Gallium-68 PSMA-PET combined with MRI received Fast Track designation as a diagnostic strategy intended to improve prostate cancer detection prior to biopsy.
Practice Considerations
- Most programs remain in early- to mid-stage development, and Fast Track designation should not be interpreted as evidence of clinical efficacy.
- The update highlights continued investment in biomarker-driven oncology development, including KRAS-targeted therapies and bispecific immunotherapy approaches.
- The prostate cancer imaging designation reflects growing interest in improving pre-biopsy diagnostic accuracy and potentially reducing unnecessary invasive procedures.
